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Abstract
Down syndrome (DS) is a complex genetic syndrome characterized by intellectual disability, dysmorphism and variable
additional physiological traits. Current research progress has begun to decipher the neural mechanisms underlying
cognitive impairment, leading to new therapeutic perspectives. Pentylenetetrazol (PTZ) has recently been found to have
positive effects on learning and memory capacities of a DS mouse model and is foreseen to treat DS patients. But PTZ is also
known to be a convulsant drug at higher dose and DS persons are more prone to epileptic seizures than the general
population. This raises concerns over what long-term effects of treatment might be in the DS population. The cause of
increased propensity for epilepsy in the DS population and which Hsa21 gene(s) are implicated remain unknown. Among
Hsa21 candidate genes in epilepsy, CSTB, coding for the cystein protease inhibitor cystatin B, is involved in progressive
myoclonus epilepsy and ataxia in both mice and human. Thus we aim to evaluate the effect of an increase in Cstb gene
dosage on spontaneous epileptic activity and susceptibility to PTZ-induced seizure. To this end we generated a new mouse
model trisomic for Cstb by homologous recombination. We verified that increasing copy number of Cstb from Trisomy (Ts)
to Tetrasomy (Tt) was driving overexpression of the gene in the brain, we checked transgenic animals for presence of
locomotor activity and electroencephalogram (EEG) abnormalities characteristic of myoclonic epilepsy and we tested if
those animals were prone to PTZ-induced seizure. Overall, the results of the analysis shows that an increase in Cstb does not
induce any spontaneous epileptic activity and neither increase or decrease the propensity of Ts and Tt mice to myoclonic
seizures suggesting that Ctsb dosage should not interfere with PTZ-treatment.
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Introduction
Down syndrome, resulting from the presence of an extra copy of
human chromosome 21 (Hsa21 for Homo sapiens chromosome
21), is the major genetic cause of cognitive disabilities [1]. DS is
associated with learning and memory defects, implicating
dysfunction of hippocampal pathways [2–5]. The mouse Ts65Dn
model, trisomic for a segment of mouse chromosome (Mmu for
Mus musculus) 16 containing approximately 60% of the Hsa21
orthologous genes [6], has been shown to mimic DS deficits in
learning and memory [7,8]. Ts65Dn mice were used to test several
therapeutic interventions to improve learning and memory [9].
Two independent studies successfully administrated chronic low
dose of the GABAA antagonist PTZ to restore LTP and cognition
in Ts65Dn mice [10,11]. PTZ is also known for its ability at higher
dose to induce seizure, by impairing GABA-mediated inhibition
[12,13]. Frequency of epilepsy in DS has been reported ranging
from 6 to 17% [14–16] with phenotype features varying with the
age of the patient and a triphasic distribution of seizure onset
(infancy, early adulthood and late onset) having been suggested
[17]. A prevalence reaching 46% in patients over 50 years was
even reported [14,16]. Thus using PTZ to treat DS people raises
concerns about potential long-term side effects.
An interesting candidate for susceptibility to epilepsy in DS is
CSTB, a gene located on Hsa21 and shown to be overexpressed in
the brain of DS individuals [18], but whose mouse ortholog is
absent in the Ts65Dn model used to test PTZ treatment.
Mutations in CSTB are associated with progressive myoclonus
epilepsies (PMEs) in Unverricht-Lundborg disease (EPM1;
OMIM254800) [19–21] a disease that shares features with late
myoclonic epilepsy observed in DS [22]. At least 10 isoforms of
CSTB have been reported with pathologic influence, leading to
EPM1. In 90% of the cases, EPM1 results from a down regulation
of gene expression due to the expansion of a dodecamer repeat in
the putative promoter of CSTB [19–21], with a polymorphism of
2 or 3 copies existing in individuals without EPM1 [23] and
asymptomatic pre-mutation alleles of 12–17 repeats leading to
reduced mRNA levels [24]. As expected Cstb loss-of-function
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postulated that CSTB deficiency increases susceptibility to
generalized tonico-clonic seizures and seizure-induced cell death
[26]. Reduced density of GABA-immunoreactive cells in the
hippocampus of Cstb-deficient mice and increased susceptibility to
kainate-induced seizures of those mice suggest a defect of the
GABAergic system. If increased synthesis of CSTB after induced
seizures has been suggested to have an anti-apoptotic role [27], it is
not known what effect might have a persistent increased amount of
cystatin B on the cell. While human cystatin C, another protein
from the same family, is a well known amyloid protein involved in
human cerebral amyloid angiopathy [28], cystatin B was shown to
interact with amyloid-beta peptide of Alzheimer’s disease both in
vitro and in the cells and can form aggregates in cells [29,30].
Therefore increased Cstb might, as well as its absence, have a
deleterious effect on the cell.
In the present study, we tested two related hypothesis regarding
a potential role of Cstb in the pathogenesis of epilepsy: (1)
Overexpression of Cstb, like underexpression, could induce EPM1-
like phenotypes; and (2) Cstb could be a candidate gene for
increased susceptibility to epilepsy in DS. We took advantage of a
genetically engineered transgenic line carrying a tandem duplica-
tion of Cstb to test if change in Cstb dosage could induce a
spontaneous epileptic activity or modify PTZ-induced seizure
susceptibility. After verifying the increased gene expression in
heterozygous (trisomic-Ts) and homozygous (tetrasomic-Tt) mice,
we tested those mice for locomotor and electrophysiological
brain activities, and propensity to clonic seizures after PTZ
administration.
Results
Creation of transgenic mice trisomic and tetrasomic for
Cstb by generating a tandem duplication of Cstb
The tandem duplication of Cstb on MMU10 was generated in
vivo by chromosomal engineering [31]. The vector containing the
genomic sequence (MMU10 229945–237205 in NCBIm37 mouse
assembly) that bears the Cstb allele was selected from the 59Hprt
library [32]. It was integrated into the Cstb locus by targeting in
HM-1 ES cells [33] and confirmed by different restriction enzymes
and specific probes (Fig. 1). We derived a Cstb,tm1Yah. mouse
line from the ES with the integrated vector (T). Mosaic animals
were bred with B6 mice to establish a heterozygous (trisomic) line.
Afterward, Ts animals were intercrossed to produce 2n, Ts and Tt
mice for experimental analyses. We observed a normal Mendelian
segregation ratio for both the heterozygous and homozygous
animals. Some animals reached the age of 6 month without any
apparent pathology developing. Hence, the transgenic animals
were all viable, fertile and healthy.
Increased Cstb expression in the liver and brain of Cstb
transgenic mice
We verified that the presence of additional copies of Cstb
resulted in increased expression of the gene in the transgenic mice.
For this, we measured Cstb mRNA in the liver and brain of 2n, Ts
and Tt mice. Levels of transcript expression were assessed in total
RNA extracts from livers (8 2n; 8 Ts; 6 Tt) and brains (8 2n; 8 Ts;
7 Tt) by quantitative real-time PCR (QRT-PCR) and relative
amount of transcripts were represented with one wild-type sample
taken as the reference amount (equal 1). In both liver and brain,
Cstb expression was increased by about two folds (fold change
1.965, U-test p,0.001 for the liver; fold change 1.72 U-test
p=0.021 for the brain) in the trisomic mice and by about 3 folds in
the tetrasomic ones (fold change 2.994, U-test p,0.001 for the
liver; fold change 3.08, U-test p,0.001 for the brain) (Fig. 2).
Hence, the presence of additional copies of Cstb results in over
expression of the gene. However, increased expressions in trisomic
and tetrasomic mice were higher than expected from the number
of added copies of the gene (1.5 fold for one additional copy and 2
fold for 2 additional copies). We further investigated if the
increased transcript expression also resulted in an increased
amount of protein. Amount of Cystatin B was assessed in the brain
of 2n (4 animals), Ts (3 animals) and Tt (4 animals) using Western
blot analysis. Quantity of protein was normalized to the amount of
b-tubulin and relative protein levels in each animal were
calculated with one 2n animal as the reference amount (equal
1). Increased in protein levels were observed in (Ts) (fold change
1.5, Student’s t-test, p=0,067) and Tt (fold change 2.2, Student’s t-
test, p=0.0004) mice, but was slightly lower that the increase
observed at the mRNA level.
Looking for signs of ataxia, cerebellar atrophy and
epilepsy in Ts and Tt mice: locomotion, histological
analysis and electrophysiological recordings
Knowing that Cstb is implicated in progressive ataxia and
myoclonic epilepsy, we aimed to check if an excess of cystatin B
could trigger the same type of pathologies. Mice were tested for
spontaneous locomotor activity in an open-field, for skilled
behaviour in rotarod and for spontaneous epileptic cortical
activity. Fifteen 2n, ten Ts and eight Tt mice about 6 month of
age were tested. Locomotor activity was scored by measuring the
travelled distance and the number of rears for a period of 30 min
(Fig. 3a, b). Ataxia is characterized by wide-base gait walking with
occasional falling upon hindlimb rearing. There was no sign of
such atypical behaviour observed and no difference in the distance
travelled and the number of rears between the different groups of
mice. The 3
rd fall latency was not significantly different between
groups on the first five sessions of rotarod (low speed: 1–5 rpm;
data not shown) and was significantly different between groups on
sixth session (ANOVA: p=0.03), but not on the following sessions
(high speed: 1–20 rpm; Fig. 3c). Post-hoc comparison by the
Student’s t-test shows that the 3
rd fall latency was lower in Tt male
mice than in 2n male mice on the 6
th session (S6 in Fig. 3c;
p=0.02); the other post-hoc comparisons did not reveal significant
difference. We compared gross histology of cerebellar tissues from
2n, Ts and Tt mice aged between 6 and 10 months. The
cerebellum of Cstb knock-out mice characterized by a dramatic
shrank evident at the macroscopic level and by a drastic reduction
of the cell density of the granule cell layer visible at low-resolution
analysis of histological sections [25,26]. We could see no such sign
of cerebellar atrophy (data not shown) and no visible change in the
density of the granular cell layer in the cerebellum of in all
populations of mice (Fig. 3d).
Spontaneous myoclonic seizures observed in Cstb-deficient mice
appear already at one month of age and are associated with
characteristic EEG [26]. This phenotype was investigated in
young 2n, Ts and Tt adult mice. For this, mice were monitored for
their cortical activity using EEG recording. No seizures or
epileptiform abnormalities were detected in wild-type or in
transgenic mice suggesting an absence of any epileptic activity
for both populations of mice (Fig. 4).
Testing susceptibility of Cstb trisomic and tetrasomic
mice to PTZ-induced seizures
To see if the presence of additional copies of Cstb could modify
the mouse susceptibility to seizure, we challenged control 2n, Ts
and Tt mice to the seizure-provoking agent PTZ. PTZ decreases
Impact of Increased Cstb Dosage
PLoS ONE | www.plosone.org 2 November 2011 | Volume 6 | Issue 11 | e27845the potency of GABA-mediated inhibition in brain [34] and,
depending on dosage, can produce myoclonic jerks, tonico-clonic
convulsions followed or not by tonic seizures in animals. Mice
were injected with increasing doses of PTZ and the number of
mice showing tonico-clonic seizures was recorded for each genetic
group and at different doses. In all three groups of mice, the
administration of PTZ induced convulsions in a dose-dependent
manner (Table 1 and Fig. 5a). The ED50 values of PTZ for Ts and
Tt animals were respectively 70.5 [65.5–73.6] and 66.9 [62.0–
70.0], and did not differ significantly from the ED50 value for
control 2n animals, which was 68.9 [60.6–73.4]. The logistic
regression model including the genotype of the mouse and the
PTZ dose and their interaction to predict the logit of the
probability of seizure indicated a statistically significant effect of
the PTZ dose (p,0.001) but no significant effect of the genotype
(p=0.33) or the interaction (p=0.26). No significant odds-ratio
was found when comparing Ts and Tt mice to 2n mice (Table 2).
Thus increase in expression of the Cstb gene in Ts and Tt animals
did not enhance the susceptibility to PTZ-induced seizures. Time
latency between PTZ administration and the onset of seizure was
very variable among each genotype group with few animals with a
very late onset of seizure (Fig. 5b). The log-rank test comparing
latency curves from the three genotypes (Fig. 5c) indicated no
significant differences (p=0.44). Whereas the differences in the
mean values among the treatment groups are greater than would
be expected by chance, difference among genetic groups within
each single PTZ dose was not significant (see Table 3). While a
monotonic dose-effect related to clonic seizure latency was
observed for 2n and Tt animals, this was not the case for the Ts
(Table 3). However, the dose-response curves (Fig. 5a) between
genotypes are similar suggesting that this effect is probably an
experimental artifact and has no biological mean.
Figure 2. Analysis of Cstb expression in the liver and cerebrum of mice that are disomic (2n), trisomic (Ts) and tetrasomic (Tt) for
Cstb. (a) Real-time PCR analysis: mRNA levels are expressed relative to the disomique control. Data are represented as mean6sem. In both liver and
cerebrum, Cstb expression is increased by ,2 folds in the Ts and by ,3 folds in the Tt mice. (b) Western blot analysis: band intensities were estimated
using ImageJ and normalized against the loading control b-tubulin. Protein levels are represented as fold-changes relative to the 2n control and
represented as mean6sem. Amounts of cystatin B are increased by about 1.5 fold in Ts and by about 2.3 fold in Tt brains. Inset shows one
representative band for 2n, Ts and Tt.
doi:10.1371/journal.pone.0027845.g002
Figure 1. Generation of a tandem duplication of the Cstb gene on Mmu10. The targeting vector containing a loxP site (green arrow), a
selectable antibiotic resistance gene (neo), and the 59part of the Hprt gene were integrated in the Cstb locus (Cstbtm1Yah), leading to the tandem
duplication of Cstb. The Cstb,tm1Yah. allele was checked by Southern analysis with probes A and B, and BstXI restriction enzyme, showing a
fragment of 9.6 kb for the wild-type allele (wt) and a 11.6 kb fragment (probe A) or a 13.2 kb fragment (probe B) for the Cstb,tm1Yah. (T) allele.
doi:10.1371/journal.pone.0027845.g001
Impact of Increased Cstb Dosage
PLoS ONE | www.plosone.org 3 November 2011 | Volume 6 | Issue 11 | e27845Discussion
We report the generation and study of a mouse model bearing
tandem duplication of the Cstb gene, leading to trisomy of the gene
in Cstb,tm1Yah. heterozygous mice and to tetrasomy in
homozygous mice. Presence of 3 copies of Cstb in Ts and of 4
copies in Tt mice results in respectively 2 and 3 folds over
expression compared to control disomic expression. Two fold
overexpression of Cstb in Ts mice is in accordance with reports of
2.15 fold change for Cstb expression in DS adult brains [18], 1.94
fold change in primary cultures of human fetal cells [35] and an
average log ratio of 1.77 in astrocyte cell lines derived from fetal
brains [36]. However, other studies, one on a lymphoblastoid cell
line [37] and one on fetal hearts at 18–22 weeks of gestation [38],
found that there was no significant difference in the levels of
transcripts expression between the trisomic and diploid tissues
analyzed. This indicates that compensatory mechanisms exist for
the expression of Cstb in different tissues. It hence seems that, at
least in the brain, adding one copy of the Cstb gene into the
genome results in an about 2-fold over-expression of the
transcripts in both human and mice. However, when looking at
the protein level, the overexpression in Ts and Tt animals was
lower than that observed at the mRNA level, indicating that some
compensatory mechanism occurs at the translation level. The
effect of the presence of a third gene copy on the expression of
HSA21 genes in DS has been mostly studied at the transcript level
following the development of high-throughput transcriptome
analysis techniques. However, much less has been carried out on
the proteome analysis and we could find no report about the level
of Cystatin B in DS patients. Contrary to other T21 transgenic
mouse models for single candidate genes [39–49] that often have a
very high overexpression of the gene, our model seems to be more
appropriated to study the effect of Cstb in T21. In addition, the
role of CSTB in EPM1 characterized by an association of epilepsy,
myoclonus and progressive neuronal deterioration [50] makes it a
good candidate gene for the increased susceptibility of DS patients
to epileptic seizures and the Cstb,tm1Yah. mouse provides a
model to test this.
Although the susceptibility to epilepsy is higher in persons with
DS than the general population, the mechanisms by which
seizures are generated in DS have received little attention.
Cognitive functions that are particularly affected in DS are spatial
learning and memory [51–56], two functions that require the
hippocampus and prefrontal cortex. Several studies suggested that
impairment of these functions was the result of an alteration in the
number of excitatory synapses [57–60]. This hypothesis was
comforted by functional explorations of the hippocampus and the
neocortex of Ts65Dn mice which presented an increased
GABAergic inhibition [60–63] and by the beneficial effect of the
use of GABA receptor antagonists on the memory performance of
Ts65Dn mice [10,11]. However, if epilepsy has been related to the
alteration in the balance between excitation and inhibition, this
change of balance is in the favor of an increased excitation and not
an increased inhibition. Hence, additional mechanisms might
underlie epileptic seizure in DS and finding the relationship
between the epileptic anomalies and the presence of an extra
Hsa21 remains essential not only to treat those symptoms, but also
to be aware of all the possible side effects that might trigger the
Figure 3. Locomotor activity of 2n, Ts and Tt mice and histological analysis of the cerebellum. (a) and (b) Mean 6 SEM for the total
distance travelled and the number of rears during the 30 min session in the open field. (c) Mean 6 SEM for the latency to fall from the ratorod. (d)
Hematoxylin/eosin-stained coronal sections in through the cerebellum of 6 month-old 2n, Ts and Tt mice (61,25 and 640 magnifications) showing
similar granular cell layers for the different mice. The position of the enlarged zone in the higher magnifications is shown by the boxes in the top
panel.
doi:10.1371/journal.pone.0027845.g003
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antagonists such as PTZ.
We selected CSTB as a candidate Hsa21 gene for the increased
susceptibility of DS persons to epileptic seizure because of its
implication in EPM1, a type of myoclonic epilepsy characterized
by stimulus-sensitive myoclonic seizures and slowly progressive
cerebellar ataxia. 90% of EPM1 patients have an unstable
dodecamer repeat expansion of at least 30 copies, located in the
putative promoter of CSTB 175 bp upstream from the translation
initiation codon, that leads to a drastic down regulation of CSTB
gene expression [19–21,50,64–67]. Hence, the CSTB mRNA
levels in patients homozygous for the expansion mutations was
found to be less than 10% of that in the controls [67]. Whereas loss
of function mutations in CSTB underlies the myoclonic epilepsy
and progressive neurological deterioration observed in EPM1, the
effect of increased CSTB expression in T21 is unknown and there
is no evidence whether this gene is also responsible of the higher
prevalence of epileptic seizures observed in the DS population.
CSTB encodes cystatin B, a member of the cystatins or stefins
family of protease inhibitors [68,69], which main action is to
inhibit the functions of cathepsins B, H, L and S, some lysosomal
cysteine proteases [68–74]. Hence, cystatin B is thought to play a
role in protecting against the proteases leaking from lysosomes, but
little is known about its physiological functions and it probably also
interacts with other cellular proteins. Di Giaimo and co-workers
have reported in vitro interactions of CSTB with rat neurofilament
light polypeptide, activated protein kinase C receptor, brain b-
spectrin, a novel, myotubularin-related and a novel, unknown
protein in cerebellar tissue, suggesting a role in cell growth and
differentiation [75]. Discovery of neuronal apoptosis in the EPM1
mouse model deficient for cystatin B [25] and identification of
increased expression of Cstb mRNA and protein in a rat kindling
model of epilepsies [27] suggest a physiological role for this protein
in the maintenance of normal neuronal structure. According to
this, increased Cstb expression should result in a more protective
role against epilepsy. Mo ¨ller and collaborators (2001) however
characterized epileptic features in DS patients with late onset
myoclonic epilepsy and found generalized epileptiform discharges
and EEG similar to those observed in EPM1 [22]. We cannot
therefore exclude that over expression of Cstb akin to its deficiency,
may produce epileptic phenotype via the perturbation of some
molecular pathway balance. A convergent effect of both increase
and decrease amounts of a same protein has already been
described in the literature, with, for example, deregulation of
Dyrk1A levels leading to motor and learning impairments in both
heterozygous Dyrk1A mice and transgenic mice overexpressing
Dyrk1A [1,76,77]. The finding that both over expression of wild-
type or EPM1 mutants of cystatin B in neuroblastoma cells
generates cytoplasmic aggregates [30] has suggested that cystatin B
in vivo has a polymeric structure sensitive to the redox
environment. Knowing that evidence of oxidative stress was
reported in individuals with DS, it is not inappropriate to postulate
Figure 4. Electrocorticographic activity of 2n, Ts and Tt mice. Trace from left and right hemisphere show normal cortical activity. Calibration:
30 mV/mm.
doi:10.1371/journal.pone.0027845.g004
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epileptic susceptibility observed in DS. EPM1 onset has been
related to latent hyperexitability and, upon discovery of reduced
density of GABA-immunoreactive cells in the hippocampus of
Cstb-deficient mice, scientists have postulated that loss of
GABAergic inhibition plays a role in this phenomenon [26]. We
therefore analysed Ts and Tt mice for both EPM1-like phenotype
and tested the effect of increased expression of Cstb on the
susceptibility or resistance to PTZ-induced clonic seizures.
Observation and analysis of Ts and Tt mice for locomotion
activity in an open-field did not reveal any gross lack of
coordination of muscle movements such as wide-based gait or
falling upon hindlimb rearing that are characteristic of ataxia.
Whereas a slight decreased in performance was found for Tt males
Table 1. Analysis of PTZ-induced tonico-clonic seizure in 2n, Ts and Tt mice.
PTZ dose
(mg/kg) PTZ-treated animals (N) Clonic seizure incidence (N) Clonic seizure incidence (%)
2n Ts Tt 2n Ts Tt 2n Ts Tt
60 18 18 18 4 1 5 22.2 5.6 27.8
70 14 18 14 9 10 7 64.3 55.6 50
75 31 45 30 22 34 25 71 75.6 83.3
80 19 30 12 12 21 11 63.2 70 91.7
90 18 17 16 16 14 16 88.9 82.4 100
The number of PTZ-treated mice, the number of convulsing mice and the percentage of convulsing mice are given for each genotype and PTZ dose.
doi:10.1371/journal.pone.0027845.t001
Figure 5. Evaluation of susceptibility of 2n, Ts and Tt mice to PTZ-induced seizure. (a) Dose-response curves showing the ratio of the
number of convulsing mice observed (obs) or predicted (pred) to the total number of injected animals for each PTZ dose. (b) Distributions of latencies
of seizure for each genotype at the different doses of PTZ administered. (c) Global survival curves of 2n (blue), Ts (red) and Tt (green) mice (probability
of seizure according to time, latencies right censored at 1800 sec).
doi:10.1371/journal.pone.0027845.g005
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difference was not found again in the later sessions, and no
significant locomotor deficit could be measured in transgenic
animals. Morphological and histological analysis of the cerebellum
did not reveal any atrophy or severe decrease of the density of the
granule cell layer, the neuropathological hallmark of the Cstb-
deficient mice [25]. EEG analysis enables to visualize events such
as interictal discharges (spikes) and the recently discovered high
frequency activities (fast ripples) in epileptic patients or animal
models even in the absence of a seizure. EEG recorded in the 2n,
Ts and Tt mice showed a strictly normal activity, indicating that
these animals were not epileptic. Looking for the implication of
Cstb in susceptibility to PTZ-induced seizure, we subjected 2n Ts
and Tt animals to increased dose of PTZ. Whereas there was an
effect of the increasing dose of PTZ on the number of convulsing
mice and the latency time between the injection and convulsion,
no effect of the genotype could be observed. Our analysis did not
reveal any increase in susceptibility or resistance to PTZ of the Ts
and Tt mice compared to 2n and increased expression of Cstb does
not alter susceptibility to tonico-clonic induced seizure triggered by
PTZ. Presence of 3 copies of the CSTB gene is probably not
involved in susceptibility to epileptic seizure in the DS population.
However, we cannot rule out an involvement of this gene in
seizure susceptibility, not via an increased of dosage, but due to the
presence of more than one allele of the same deleterious allelic
variant, which then becomes sufficient to overcome the buffering
of a normal allele, a mechanism that has already been suggested
for the pathologic contribution of trisomic genes in DS. Indeed,
whereas EPM1 is rare in western Europe, it was found to be
common in north Africa where about 60% of the patients share
the same haplotype, thus establishing a founder effect in this
population [78]. Furthermore, in addition to down-regulation of
gene expression found in 90% of the EPM1 cases, five coding-
region mutants have also been found, usually heterozygous with
the repeat expansion [67]. Among these mutants, mutants R68X
and G4R were more especially prone to form aggregates in cells
[79]. This allelic variant affect would explain the penetrance of the
epileptic phenotype in DS. In this point of view, it would be of
interest to analyse the genetic background that is known to
influence the presence or severity of myoclonic seizures in Cstb2/2
mutant mice [25].
Increased susceptibility to epilepsy in DS patients is surprising
regarding the finding that they have been shown to have excess
GABA-mediated inhibition [80]. Nervertheless other mechanisms
might underlie epileptic susceptibility in DS and additional Hsa21
genes could influence seizure-susceptibility. Searching for Hsa21
mouse orthologous genes implicated in seizure according to
mammalian phenotype ontology using the Mouse Genome
Informatics (MGI) group (www.informatics.jax.org), five genes in
addition to Cstb were listed that, when mutated, are associated with
a variety of seizure related phenotypes. Among those genes, Kcnj6
(Girk2) codes for a ion channel subunit, ion channels representing
66% of the currently known Mendelian human epilepsy gene, and
a point mutation in this gene causes ataxia, tremor and tonico-
clonic seizures in the weaver mouse [81]. However, studies in
human have so far failed to demonstrate an association between
KCNJ6 and epilepsy [82,83]. Dscam, a member of the immuno-
globulin (Ig) superfamily, has been implicated in cell migration and
sorting, axon guidance, formation of neural connections and
synaptic plasticity [84,85]. Synj1 codes for a nerve terminal protein
that appears to be involved in synaptic vesicle recycling [86] and
its presence in three copies in the Ts65Dn model results in altered
phosphatidylinositol-4,5-bisphosphate metabolism in the brain
[87]. The transcription factor encoding gene Olig2 is implicated
in glial development [88] and neuronal repair after brain injury
[89]. These first four genes are found on the trisomic region
present in the Ts65Dn model that served to test chronic low-dose
PTZ treatment of T21 memory deficits. The last gene, however, is
present on Mmu10: Adarb1 is a gene coding for a RNA-editing
Table 2. Effect of the dose of PTZ and of the genotype on the
probability of seizure (logit scale).
Effect
Odds-ratio
(95% Wald CI)
Wald Chisq
test p-value
Dose (mg/kg) 1.14* (1.10–1.18) ,0.001
Mouse Type - 0.12
2n 1
Ts 0.92** (0.50–1.70)
TT 1.79 (0.89–3.59)
The odds-ratios (OR) are estimated from a logistic regression model. The dose
of PTZ is the only statistically significant effect observed. Increasing the
administered dose of one mg/kg leads to a significant increase of the
probability of seizure. No significant odds-ratio was found when comparing Ts
and Tt mice to 2n mice.
doi:10.1371/journal.pone.0027845.t002
Table 3. Effects of the dose of Cstb and of the genotype on time of onset of tonico-clonic seizure.
Clonic seizure latency and number of censored/N, mean* (standard error)
Dose (mg/kg) 2n Ts Tt
Test of equality
over genotypes
1
60 14/18 708.8 (37.7) 17/18 470.0 (na) 13/18 941.0 (58.5) 0.23
70 5/14 608.6 (59.0) 8/18 547.2 (47.9) 7/14 807.8 (101.9) 0.82
75 9/31 587.4 (82.1) 11/45 468.3 (47.8) 5/30 541.4 (114.0) 0.21
80 7/19 342.3 (28.7) 9/30 625.8 (101.9) 1/12 453.1 (159.1) 0.13
90 2/18 338.9 (49.7) 3/17 497.8 (151.8) 0/16 437.0 (104.0) 0.92
Test of equality over doses
1 0.0003 ,0.0001 ,0.0001
The number of censored mice among the total number of mice, the mean latencies and their standard error estimations for each genotype group and dose of PTZ are
presented.
1Statistical comparison of genetic groups within each PTZ dose and comparison of doses within each genotype group were done using the log-rank test.
*Mean latencies and their standard errors estimations were restricted to the largest seizure time among non censored observations.
doi:10.1371/journal.pone.0027845.t003
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leads to seizure susceptibility and could hence have an influence
on susceptibility to PTZ treatment [90]. Finally, SOD1, a major
cytoplasmic antioxidant enzyme converting superoxide radicals to
molecular oxygen and hydrogen peroxide and whose gene is
present on Hsa21 and Mmu17, was recently identified as a
possible epileptic biomarker in a proteomic analysis of cerebro-
spinal fluid (CSF) from patients with temporal lobe epilepsy (TLE)
[91]. Hence, other gene candidates remain to be tested and there
are still concerns over what the long-term effects of chronic pro-
epileptic drug such as PTZ might be in a population at higher risk
of epileptic seizure such as DS people.
Materials and Methods
Generating a tandem duplication of the Cstb gene on
MMU10
A tandem duplication of Cstb was obtained during the insertion
by homologous recombination of a targeting vector for Cstb
isolated from the 59Hprt library [32] in HM-1 embryonic stem (ES)
cells [33]. The region of homology in the insertion vector contains
the three alleles of Cstb and the insertion of the vector leads to the
formation of two entire Cstb genes separated by the vector
backbone (Fig. 1). Recombinant ES cell clones were selected
against neo and verified by Southern blot analysis using two
external probes. They were then injected into C57BL/6J (B6)
blastocysts to generate chimera. These animals were crossed with
B6 mice to obtain the corresponding mouse line, named
Cstb,tm1Yah.. After establishment of the line on the B6
background (backcross level higher than N7), heterozygous mice
(one chromosome containing the tandem duplication and one
wild-type chromosome) were intercrossed to give disomic (2n; two
wild-type chromosomes), trisomic (Ts; heterozygous for the
chromosome containing the tandem duplication) and tetrasomic
(Tt; homozygous for the chromosome containing the tandem
duplication) mice for Cstb.
Mouse genotyping
Mice were genotyped by Southern blot analysis in standard
conditions. Briefly, 10 mg of genomic tail or ES cell DNA extracts
were digested with the BstXI enzyme and separated by
electrophoresis through 0.8% agarose gel. The digested DNA
was transferred to Hybond nylon membrane (GE Healthcare,
Chalfont St Giles, UK) and hybridized with a specific DIG-
labeling probe (probe B in Fig. 1) (Roche, Mannheim, Germany).
Autoradiography was performed using Kodak Biomax XAR-Films
(Kodak, Chalon-sur-Sao ˆne, France).
RNA extraction and quantitative RT-PCR analysis
Total RNA was extracted from the liver and from the brain of
2n, Ts and Tt mice using the RNAeasy
R mini-kit (Qiagen) and
RNA integrity was checked using the Agilent 2100 bioanalyzer.
cDNA synthesis was performed using the Absolute
TM 2-step
QRT-PCR SYBR Green Kit (ABgene, Epsom, UK). The primer
pairs used for QPCR amplification of Cstb and of the selected
normalization gene (Actb) are the ones designed by Lyle et al.
(2004) [92]. Primers for Cstb are in exon 2 and exon 3 of the gene.
HPLC purified FAM-TAMRA-labeled (Cstb) and HEX-TAMRA-
labeled (Actb) double dye Taqman probes were obtained from
Eurogentech. Efficiency of the Taqman assay was checked using a
cDNA dilution series from extracts of brain samples [93]. The
QPCR was performed with 15 ng of cDNA and 200 nM of each
primer in a 15 ml final reaction that contained primers for both the
tested (Cstb) and normalization gene (Actb) in a Stratagene Mx4000
with a standard amplification procedure. Reactions were made in
triplicate and the mean Ct used for measurement of the transcript
levels that were normalized against transcript levels of Actb in order
to correct the variations of the amount of source RNA in the
starting material. For each tissue, the QPCR analysis was repeated
three times (three plate runs) to check for reproducibility of the
results.
SDS-PAGE and Western blot
Ten microgram of total protein from brain extracts were
electrophoretically separated in SDS-polyacrylamide gels (17%)
and transferred to nitrocellulose membrane. Non-specific binding
sites were blocked with 5% skim milk powder in Tween Tris buffer
saline for 1 h at room temperature. Immunostaining was carried
out with a rabbit polyclonal anti-Stefin B (ab53725 from AbCam)
and a mouse monoclonal anti-b-tubulin, followed by secondary
anti-rabbit IgG and anti-mouse IgG conjugated with horseradish
peroxidase. The immunoreactions were visualized by ECL
chemoluminescence (Amerham Biosciences) and exposure to
ECL Hyperfilm (GE healthcare). Semi quantitative analysis was
performed using the ImageJ software (W. Rasband, NIH; http://
rsb.info.nih.gov/ij/).
Statistics
All quantitative results were presented as mean6s.e.m.
(standard error of the mean). For statistical analysis, levels of
mRNA and protein transcripts in Ts and Tt animals were
compared to levels in 2n mice by performing either the parametric
Fischer-Student t-test when applicable (when normality and equal
variance tests passed) or the non parametric Wilcoxon Mann-
Withney’s U-test via the Statgraphics software (Centurion XV,
Sigma plus, Levallois Perret).
Spontaneous locomotor activity and rotarod
Animals were bred under SPF conditions and were treated in
compliance with animal welfare policies from the French Ministry
of Agriculture (law 87 848). YH, as the principal investigator in
this study, was granted the accreditation 45-31 to perform the
reported experiments.
Fifteen diploid (2n), 10 Ts and 8 Tt mice (4–6 months) were
used in these tests. Spontaneous locomotor activity was measured
between 8.00 am and 13.00 pm. Each animal was individually
placed in an open-field (Acti-track, Panlab; 43643635 cm, 10
Lux) for a 30 min session. The locomotor activity was evaluated by
measures of distance travelled and number of rears [94]. Rotarod
testing was conducted between 8.00 am and 16.00 pm in an
accelerating rotarod (TSE). Animals were subjected to nine 10-
min sessions. Mice were placed on the rod, rotating at an initial
speed of 1 rpm; the speed was progressively increased from 1 rpm
to 5 rpm on the first five sessions (pretraining) and from 1 to
20 rpm on the following sessions. The mice were placed again on
the rod after two falls and were removed from the apparatus after
the third fall. The latency of the third fall was recorded (a score of
600 sec was given when the mouse fell less than three times).
Statistical analysis was done comparing each transgenic group
versus the disomic (2n) group using ANOVA followed by Student
t-tests in case of a significant Fisher test (p,0.05).
Histological analysis
Mice aged over 6 month (2 of each genotype) were deeply
anesthetized with pentobarbital and perfused intra-cardially with
30 ml of phosphate-buffered saline (PBS), followed by perfusion
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was dissected and post-fixed overnight in 4% PFA at 4uC,
dehydrated, embedded in paraffin and sectioned at 5 mm. Sections
were dewaxed, rehydrated and stained with hematoxylin and
eosin.
Electrophysiological evaluation
Presence of epileptic events was checked in freely moving
animals via electrophysiological recordings of 3 mice from each
genotype (2n, Ts and Tt). EEG recording was done by
implantation of skull surface electrodes two weeks before the start
of recording. Animals were put under general chloral hydrate
anesthesia (400 mg/kg) and midline scalp incision was made to
expose the skull. Five surface screw unipolar recording electrodes
were implanted, four bilaterally 2.5 mm from midline in the
frontal and parietal cortex, and the last one above the cerebellum
as reference. Electrodes were sealed to the dental acrylic. Animals
were allowed to recover for 15 days before experimental analysis.
EEG activity was recorded in both hemispheres with a numerical
acquisition system (Coherence, Deltamed) to detect any hypothet-
ical synchronized EEG activity. Animals were connected to the
recording system and tested within a Faraday cage. After a
15 minute habituation delay, mice were recorded for 30 min for
the two first trios (one mouse from each genotype) and overnight
for the last trio.
Testing Cstb trisomic and tetrasomic mice to PTZ-
induced seizures
To test if the presence of additional copies of Cstb increases the
susceptibility of the mice to convulsant agents, seizures were
induced in 2n, Ts and Tt mice by administration of PTZ at doses
of 60, 70, 75, 80 and 90 mg/kg, with different groups of animals
being injected for each dose. Hence, each mouse was used only
once. As this represents a total of 318 animals that could not be
generated at the same time, 10 groups of animals were produced,
each one containing the 3 different genotypes, and were tested
between 10 and 14 weeks of age. All the animals in one group
were tested the same day for one dose of PTZ. All experiments
were conducted in the same conditions between 12:00 am and
2:00 pm. Number of animals tested for each genotype and PTZ
doses are detailed in Table 1. The mice were kept in colony cages
with free access to food and tap water, under standard housing
conditions. Mice were weighted and the individual body weight
used for dose volume calculation of the PTZ. The PTZ was
injected subcutaneously. Following the injection of PTZ, mice
were placed separately into transparent Plexiglas cages and
observed for 30 min for the occurrence of tonico-clonic seizures.
The tonico-clonic seizure was defined as clonus of the whole body
lasting over 3 sec, with an accompanying loss of righting reflex.
The number of animals convulsing out of the total number of mice
tested was scored for each genotype. For animals that were
convulsing, the latency time between the injection and the first
tonico-clonic seizure was recorded for each mouse. Because males
and females did not differ in seizure susceptibility, the data consist
of measurements obtained from both groups that were represented
by an approximately equal number of animals. For ethical reason,
the few animals that have entered in a status epilepticus after that
the tonico-clonic seizure has stopped were sacrified after 1 min.
The study data were summarized and tabulated by genotype
group for the percentage of convulsing mice (Table 1). For each
genotype, the dose-response curve (number of convulsing mice/
total number of injected animals according to the PTZ dose) was
plotted and fitted by a logit model (Fig. 5a). The probability of
seizure based on the genotype of the mouse (categorical predictor),
the PTZ dose (continuous predictor), and their interaction was
then calculated using a multivariate logistic regression model.
Odds-ratios (OR) for the PTZ dose and for the increased Cstb gene
dosage (2n,Ts,Tt) was calculated as followed:
* OR for increasing the dose of one unit :=
P(seizure=dose~dz1)=1{P(seizure=dose~dz1)
P(seizure=dose~d)=1{P(seizure=dose~d)
** OR for mouse Ts compared to mouse 2n:=
P(seizure=type~Ts)=1{P(seizure=type~Ts)
P(seizure=type~2n)=1{P(seizure=type~2n)
The effects of the genotype and of the dose of PTZ on the latency
of the PTZ-induced seizure were evaluated by a stratified
comparison of the latency times of the 3 genetic groups using
log-rank tests within each dose of PTZ, because the plot of the
survival curves (Fig. 5c) of the 3 genotype groups showed that the
proportional hazard assumption was violated, and suggested that a
Cox model analysis was not applicable. For this analysis, latencies
were right censored at 1800 sec (30 min observation).
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